Trial Profile
A Pilot Study of Vigil Augmented Autologous Tumor Cell Immunotherapy in Combination With Pembrolizumab PD-1 Inhibitor for Patients With Advanced Melanoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Bi-shRNAfurin-GM-CSF-loaded tumour cell vaccine (Primary) ; Pembrolizumab
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Gradalis
- 26 Sep 2017 Status changed from active, no longer recruiting to completed.
- 27 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 04 May 2017 Planned End Date changed from 1 Sep 2017 to 1 May 2018.